Litigation Could Make Vaccines Extinct

it has the legislative model in hand

Written byJames Wood
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Brad Fitzpatrick

Vaccines have eradicated some killer diseases and protected against others. But they face eradication themselves – by litigation. As the United States rushes to defend itself against bioterrorism by developing vaccines against biological agents, Congress must pass legislation to ensure that vaccines themselves do not become extinct.

All vaccines carry risks, including side effects such as encephalitis. For example, severe allergic reactions, such as breathing problems and shock, can occur in less than one in a million doses of diphtheria, tetanus pertussis vaccine.1 Almost all US children enjoy the health benefit from immunization, but a tiny proportion, despite efforts to make the vaccine safe, have severe side effects. Before Congress acted in 1986, these children often had no financial recourse2 for their medical and rehabilitative needs other the tort system.

The result was a dwindling supply of vaccines and an increased cost of inoculations. Case in point: The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform